In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Dynavax (DVAX), with a price target of $30. The company’s shares closed yesterday at $6.53, close to its 52-week low of $6.22.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.8% and a 50.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dynavax with a $27 average price target, representing a 313.5% upside. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Based on Dynavax’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $39.97 million. In comparison, last year the company had a GAAP net loss of $38.96 million.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
